{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:05:21Z","timestamp":1772449521352,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03094-5","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T06:53:46Z","timestamp":1769928826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pegylated interferon-\u03b1-2b add-on therapy to renal function for chronic hepatitis B patients who were treated with tenofovir disoproxil fumarate: a retrospective real-world study"],"prefix":"10.1186","volume":"23","author":[{"given":"Tian-Bao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Qiang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"issue":"1","key":"3094_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10238-025-01584-4","volume":"25","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhang Y, Jiang W. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments. Clin Exp Med. 2025;25(1):57.","journal-title":"Clin Exp Med"},{"issue":"2","key":"3094_CR2","doi-asserted-by":"publisher","first-page":"2417737","DOI":"10.1080\/0886022X.2024.2417737","volume":"46","author":"Y Guo","year":"2024","unstructured":"Guo Y, Li S, Wei J, Luo M, Liu H. The relationship between HBV antigens deposition in kidneys and renal prognosis in IgA nephropathy patients infected with HBV. Ren Fail. 2024;46(2):2417737.","journal-title":"Ren Fail"},{"issue":"6","key":"3094_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.cgh.2014.11.021","volume":"13","author":"V Mallet","year":"2015","unstructured":"Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol. 2015;13(6):1181\u20138. e1181.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3094_CR4","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.3389\/fmicb.2022.980250","volume":"13","author":"MJ Peng","year":"2022","unstructured":"Peng MJ, Guo XQ, Zhang WL, Chen J, Kang W, Yang XF, Guo Y, Zhang Y. Effect of pegylated interferon-alpha2b add-on therapy on renal function in chronic hepatitis B patients: A real-world experience. Front Microbiol. 2022;13:980250.","journal-title":"Front Microbiol"},{"issue":"1","key":"3094_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12985-017-0712-x","volume":"14","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang WL, Pang XW, Wang LX, Wei X, Huang CX, Bai XF, Han S, Liu LN, Lian JQ. Effect of 48-week pegylated interferon alpha-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B. Virol J. 2017;14(1):49.","journal-title":"Virol J"},{"issue":"4","key":"3094_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7869\/tg.295","volume":"36","author":"A Jaryal","year":"2015","unstructured":"Jaryal A, Kumar V, Sharma V. Renal disease in patients infected with hepatitis B virus. Trop Gastroenterol. 2015;36(4):220\u20138.","journal-title":"Trop Gastroenterol"},{"issue":"2","key":"3094_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u201383.","journal-title":"J Hepatol"},{"issue":"1","key":"3094_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"issue":"4","key":"3094_CR9","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"6","key":"3094_CR10","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u201342.","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"3094_CR11","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.cgh.2018.08.037","volume":"17","author":"S Trinh","year":"2019","unstructured":"Trinh S, Le AK, Chang ET, Hoang J, Jeong D, Chung M, Lee MH, Wang U, Henry L, Cheung R, Nguyen MH. Changes in renal function in patients with chronic HBV infection treated with Tenofovir disoproxil fumarate vs Entecavir. Clin Gastroenterol Hepatol. 2019;17(5):948\u201356. e941.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3094_CR12","doi-asserted-by":"publisher","first-page":"e70177","DOI":"10.1002\/prp2.70177","volume":"13","author":"TD Vo","year":"2025","unstructured":"Vo TD, Nguyen HNG, Phan ST. Comparative efficacy and renal safety of Entecavir and Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B: A retrospective cohort study from Vietnam. Pharmacol Res Perspect. 2025;13(5):e70177.","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"3094_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/jbt.21560","volume":"28","author":"H Ramamoorthy","year":"2014","unstructured":"Ramamoorthy H, Abraham P, Isaac B. Mitochondrial dysfunction and electron transport chain complex defect in a rat model of Tenofovir disoproxil fumarate nephrotoxicity. J Biochem Mol Toxicol. 2014;28(6):246\u201355.","journal-title":"J Biochem Mol Toxicol"},{"issue":"2","key":"3094_CR14","first-page":"273","volume":"15","author":"F Conti","year":"2016","unstructured":"Conti F, Vitale G, Cursaro C, Bernardi M, Andreone P. Tenofovir-induced Fanconi syndrome in a patient with chronic hepatitis B monoinfection. Ann Hepatol. 2016;15(2):273\u20136.","journal-title":"Ann Hepatol"},{"issue":"7","key":"3094_CR15","first-page":"580","volume":"62","author":"S Mitra","year":"2014","unstructured":"Mitra S, Priscilla R, Rajeev K, Sauradeep S, Rajkumar S, Cherian AO. Renal tubular dysfunction associated with Tenofovir therapy. J Assoc Physicians India. 2014;62(7):580\u20132.","journal-title":"J Assoc Physicians India"},{"issue":"10","key":"3094_CR16","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1111\/jgh.70059","volume":"40","author":"E Ogawa","year":"2025","unstructured":"Ogawa E, Kohjima M, Koyanagi T, Dohmen K, Ooho A, Kawano A, Furusyo N, Kajiwara E, Satoh T, Takahashi K, et al. Five-Year effectiveness and renal safety following switching to Tenofovir Alafenamide in chronic hepatitis B patients with renal impairment. J Gastroenterol Hepatol. 2025;40(10):2560\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3094_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, et al. HBsAg loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to Nucleos(t)ide analog: new switch study. J Clin Transl Hepatol. 2018;6(1):25\u201334.","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"3094_CR18","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jvh.13126","volume":"26","author":"Q Ning","year":"2019","unstructured":"Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, Han MF, Wang Y, Zhang WH, Lu FM, Wang FS. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat. 2019;26(10):1146\u201355.","journal-title":"J Viral Hepat"},{"issue":"1","key":"3094_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12985-025-02761-3","volume":"22","author":"LJ Chang","year":"2025","unstructured":"Chang LJ, Hao CQ, Rao GR, Xu LL, Li J, Cheng Y, Zheng LJ, Wu CW, Chen HX, Chen ZR, et al. Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-alpha-2b-based therapy: a multicenter pilot study. Virol J. 2025;22(1):146.","journal-title":"Virol J"},{"key":"3094_CR20","doi-asserted-by":"publisher","first-page":"1489671","DOI":"10.3389\/fmed.2024.1489671","volume":"11","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y. Safety and efficacy of 48-week pegylated interferon-alpha-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. Front Med (Lausanne). 2024;11:1489671.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"3094_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461\u201370.","journal-title":"Ann Intern Med"},{"issue":"9","key":"3094_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"3094_CR23","doi-asserted-by":"crossref","unstructured":"Cai F, Zhang L, Zhao P, Qiu F, Mukhtar AM, Ma Y, Chen J, Han F. Urinary RBP as an Independent Predictor of Renal Outcome in Diabetic Nephropathy. Dis Markers. 2022; 2022:9687868.","DOI":"10.1155\/2022\/9687868"},{"issue":"5","key":"3094_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00726-021-02975-z","volume":"53","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Liu XQ, Zhang SQ, Qi XM, Zhang Q, Yard B, Wu YG. Correlation between serum carnosinase concentration and renal damage in diabetic nephropathy patients. Amino Acids. 2021;53(5):687\u2013700.","journal-title":"Amino Acids"},{"issue":"3","key":"3094_CR25","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","volume":"66","author":"H Izzedine","year":"2004","unstructured":"Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, Brosgart CL, Westland C, Arterbrun S, Deray G, et al. Renal safety of Adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66(3):1153\u20138.","journal-title":"Kidney Int"},{"issue":"11","key":"3094_CR26","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/ki.2010.318","volume":"78","author":"LC Herlitz","year":"2010","unstructured":"Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D\u2019Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171\u20137.","journal-title":"Kidney Int"},{"issue":"18","key":"3094_CR27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1001\/jama.2012.3954","volume":"307","author":"K Matsushita","year":"2012","unstructured":"Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307(18):1941\u201351.","journal-title":"JAMA"},{"issue":"4","key":"3094_CR28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1373\/clinchem.2011.167494","volume":"58","author":"MA Ferguson","year":"2012","unstructured":"Ferguson MA, Waikar SS. Established and emerging markers of kidney function. Clin Chem. 2012;58(4):680\u20139.","journal-title":"Clin Chem"},{"issue":"6","key":"3094_CR29","doi-asserted-by":"publisher","first-page":"e0303442","DOI":"10.1371\/journal.pone.0303442","volume":"19","author":"XL Yu","year":"2024","unstructured":"Yu XL, Sun W, Liu L, Hong K, Song H. Urinary alpha 1-microglobulin and beta 2-microglobulin as markers of early kidney injury in HIV-positive male patients on tenofovir-based antiretroviral therapy. PLoS ONE. 2024;19(6):e0303442.","journal-title":"PLoS ONE"},{"issue":"4","key":"3094_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1053\/j.ajkd.2016.03.430","volume":"68","author":"V Jotwani","year":"2016","unstructured":"Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella FJ Jr., Macatangay B, Bennett M, Parikh CR, Ix JH, Shlipak MG. HIV Infection, Tenofovir, and urine alpha1-Microglobulin: A Cross-sectional analysis in the multicenter AIDS cohort study. Am J Kidney Dis. 2016;68(4):571\u201381.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"3094_CR31","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/QAD.0000000000001070","volume":"30","author":"T Nishijima","year":"2016","unstructured":"Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, Gatanaga H. Urinary beta2 microglobulin can predict Tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate Tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS. 2016;30(10):1563\u201371.","journal-title":"AIDS"},{"issue":"1","key":"3094_CR32","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","volume":"3","author":"A Mocroft","year":"2016","unstructured":"Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte A, Kirk O, Ryom L. Data collection on adverse events of anti HIVDS. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23\u201332.","journal-title":"Lancet HIV"},{"issue":"3","key":"3094_CR33","doi-asserted-by":"publisher","first-page":"e1001809","DOI":"10.1371\/journal.pmed.1001809","volume":"12","author":"A Mocroft","year":"2015","unstructured":"Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12(3):e1001809.","journal-title":"PLoS Med"},{"key":"3094_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2147\/TCRM.S143286","volume":"13","author":"YM Yang","year":"2017","unstructured":"Yang YM, Choi EJ. Renal safety of Tenofovir and\/or Entecavir in patients with chronic HBV monoinfection. Ther Clin Risk Manag. 2017;13:1273\u201385.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"3094_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/MEG.0000000000002723","volume":"36","author":"AMA Maciel","year":"2024","unstructured":"Maciel AMA, Ferraz M, Perez RM, Brandao-Mello CE. Renal dysfunction during treatment of chronic hepatitis B with Tenofovir disoproxyl fumarate and associated risk factors. Eur J Gastroenterol Hepatol. 2024;36(4):482\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"3094_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jvh.13053","volume":"26","author":"TL Fong","year":"2019","unstructured":"Fong TL, Lee BT, Tien A, Chang M, Lim C, Ahn A, Bae HS. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from Tenofovir disoproxil fumarate to Tenofovir Alafenamide. J Viral Hepat. 2019;26(5):561\u20137.","journal-title":"J Viral Hepat"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03094-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:32:24Z","timestamp":1772447544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03094-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3094"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03094-5","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of The First Affiliated Hospital of Xinxiang Medical University (No. EC-2022-698). The Ethics Committees waived the requirement of written informed consent for participation from the participants or the participant\u2019s legal guardians\/next of kin because this was a retrospective study and only characteristics and laboratory indicators were collected. The study was conformed to the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice. The data were collected on June 2025. We had access to information that could identify individual enrolled subjects during and after data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}